Moon lab pursues development of novel therapeutics for breast, ovary, and prostate cancer


  • 2023

  • *
    Ghosh M, Kang MS, Katuwal NB, Hong SD, Jeong YG, Park SM, Kim SG and Moon YW
    PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer.
    International Journal of Molecular Sciences 2023; 24, 17086.
    Katuwal NB, Kang MS, Ghosh M, Hong SD, Jeong YG, Park SM, Kim SG, Sohn JH, Kim TH and Moon YW
    Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.
    J Exp Clin Cancer Res 2023; 42:325
    Jeong YG, Katuwal NB, Kang MS, Ghosh M, Hong SD, Park SM, Kim SG, Kim TH, Moon YW
    Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer.
    Cancers (Basel) 2023; 15, 4887
    Katuwal NB, Park N, Pandey K, Kang MS, Hong SD, Ghosh M, Kim SG, Cho YB, Hur J, Kim SK, Moon YW
    Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors.
    Anticancer Res 2023; 43: 85-95
  • 2022

  • *
    Pandey K, Katuwal NB, Park N, Hur J, Cho YB, Kim SK, Lee SA, Kim I, Lee SR, Moon YW
    Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.
    Cancers 2022; 14, 210.
  • 2021

  • *
    Hur J, Ghosh M, Kim TH, Park N, Pandey K, Cho YB, Hong SD, Katuwal NB, Kang M, An HJ, Moon YW.
    Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
    International Journal of Molecular Sciences 2021; 22: 3: 1223
    Pandey K, Lee E, Park N, Hur J, Cho YB, Katuwal NB, Kim SK, Lee SA, Kim I, An HJ, Hwang S, Moon YW
    Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.
    Genes 2021; 12: 2: 159
  • 2020

  • *
    Pandey K, Park N, Park KS, Hur J, Cho YB, Kang M, An HJ, Kim S, Hwang S, Moon YW
    Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence.
    Cancers 2020; 12: 12: 3566
    Park N, Pandey K, Chang SK, Kwon AY, Cho YB, Hur J, Katwal NB, Kim SK, Lee SA, Son GW, Jo JM, An HJ, Moon YW
    Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model. Journal for immunotherapy of cancer.
    J immunother cancer 2020; 8: 2
  • 2019

  • *
    Choi YH, Lim EJ, Kim SW, Moon YW, Park KS, An HJ.
    IL-27 Enhances IL-15/IL-18-mediated Activation of Human Natural Killer Cells
    J Immunother Cancer 2019; 7:168.
    Choi HJ, Heo JH, Park JY, Jeong JY, Cho HJ, Park KS, Kim SH, Moon YW, Kim JS, An HJ.
    A Novel PI3K/mTOR Dual Inhibitor, CMG002, Overcomes the Chemoresistance in Ovarian Cancer.
    Gynecol Oncol 2019; 153 :135-148.
    Pandey K, An HJ, Kim SK, Lee SA, Kim S, Lim SM, Kim GM, Sohn J, Moon YW.
    Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.
    Int J Cancer 2019; 145: 1179-1188.
  • 2018

  • *
    Park KS, Moon YW, Raffeld M, Lee DH, Wang Y, Giaccone G
    High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.
    Lung Cancer 116; 38-45; 2018
    Hong SR, Hur J, Moon YW, Han K, Chang S, Kim JY, Im DJ, Suh YJ, Hong YJ, Lee HJ, Kim YJ, Choi BW.
    Predictive Factors for Treatment Response Using Dual-Energy Computed Tomography in Patients With Advanced Lung Adenocarcinoma.
    Eur J Radiol 101; 118-123; 2018
    Lim SM, An HJ, Park HS, Kwon HJ, Y Kim E, Hur J, Moon YW.
    Organizing pneumonia resembling disease progression in a non-small-celllung cancer patient receiving ceritinib: A case report.
    Medicine (Baltimore) 2018; 97: e11646.
  • 2017

  • *
    Rao G, Pierobon M, Kim IK, Hsu WH, Deng J, Moon YW, Petricoin EF, Zhang YW, Wang Y, Giaccone G.
    Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.
    Sci Rep 7:7066; 2017
    Moon YW, An HJ, Koo JS, Kim GM, Han H, Park S, Kim SI, Park HS, Kim S, Kim SK, Lee SA, Hwang S, Son GW, Sohn J.
    CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator.
    Oncotarget 9: 2622-30; 2017
  • 2016

  • *
    Heo SJ, Jung I, Lee CK, Kim JH, Lim SM, Moon YW, Shim HS, Jeong J, Kim JH, Kim HR, Cho BC.
    A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 77:539-548, 2016
    Park HS, Lim SM, Kim S, Kim S, Kim HR, Kwack K, Lee MG, Kim JH, Moon YW.
    Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
    Plos One 11: e0154133, 2016
    Cho A, Hur J, Moon YW, Hong SR, Suh YJ, Kim YJ, Im DJ, Hong YJ, Lee HJ, Kim YJ, Shim HS, Lee JS, Kim JH, Choi BW.
    Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
    BMC Cancer 16: 224, 2016
    Lim SM, Park HS, Kim S, Kim S, Ali SM, Greenbowe JR, Yang IS, Kwon NJ, Lee JL, Ryu MH, Ahn JH, Lee J, Lee MG, Kim HS, Kim H, Kim HR, Moon YW, Chung HC, Kim JH, Kang YK, Cho BC.
    Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
    Oncotarget 7: 10547-56; 2016
  • 2015

  • *
    Kim HS, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Jung DH, Shin SK, Lee SK, Lee YC, Kim HR, Moon YW, Kim JH, Shim YM, Jewell SS, Kim H, Choi YL, Cho BC.
    Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.
    Oncotarget 6:2562-72, 2015
    Park JS, Lee JS, Kim EY, Jung JY, Kim SK, Chang J, Kim DJ, Lee CY, Jung I, Kim JH, Kim HR, Moon YW, Kim HS, Cho BC, Shim HS.
    The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lungcancer.
    Lung Cancer 88: 325-331, 2015
    Moon YW, Rao G, Kim JJ, Shim HS, Park KS, An SS, Kim B, Steeg PS, Sarfaraz S, Changwoo Lee L, Voeller D, Choi EY, Luo J, Palmieri D, Chung HC, Kim JH, Wang Y, Giaccone G.
    LAMC2 enhances the metastatic potential of lung adenocarcinoma.
    Cell Death Diff 22:1341-1352, 2015
    Kang CW, Jang KW, Sohn J, Kim SM, Pyo KH, Kim H, Yun MR, Kang HN, Kim HR, Lim SM, Moon YW, Paik S, Kim DJ, Kim JH, Cho BC.
    Anti-tumor activity and acquired resistance mechanism of Dovitinib (TKI258) in RET rearranged lung adenocarcinoma.
    Mol Cancer Ther pii: molcanther.0350.2015 (epub)
    Moon YW, Hajjar J, Hwu P, Naing A.
    Targeting the indoleamine 2,3-dioxygenase pathway in cancer.
    J Immunother Cancer 3:51, 2015
    Kim HS, Kim SM, Kim H, Pyo KH, Sun JM, Ahn MJ, Park K, Keam B, Kwon NJ, Yun HJ, Kim HG, Chung IJ, Lee JS, Lee KH, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Shin SK, Lee SK, Kim HR, Moon YW, Lee YC, Kim JH, Paik S, Cho BC.
    Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
    Oncotarget 6: 44971-84; 2015
  • 2014

  • *
    Park KS, Raffeld M, Moon YW, Xi L, Bianco C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, Subramaniam D, Mok T, Rosell R, Luo J, Salomon DS, Wang Y, Giaccone G.
    CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    J Clin Invest 124:3003-3015, 2014
  • 2013

  • *
    Moon YW, Lee S, Park BW, Kim EK, Kim SI, Koo JS, Park S, Kim MJ, Chung HC, Kim JH, Sohn J.
    S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.
    BMC Cancer 13:583, 2013
  • 2012

  • *
    Jung M, Koo JS, Moon YW, Park BW, Kim SI, Park S, Lee SH, Hong S, Rha SY, Chung HC, Kim JH, Sohn J.
    Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.
    PLoS One 7(9):e45127, 2012
  • 2011

  • *
    Moon YW, Park S, Sohn JH, Kang DR, Koo JS, Park HS, Chung HC, Park BW.
    Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen.
    J Cancer Res Clin Oncol 137: 1123-1130, 2011
  • 2010

  • *
    Moon YW, Rha SY, Shin SJ, Chang H, Shim HS, Roh JK.
    Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators.
    J Cancer Res Clin Oncol 136:387-394, 2010
    Moon YW, Sohn JH, Choi HJ, Chang H, Park BW, Kim SI, Park S, Koo JS, Kim YT, Roh JK, Chung HC, Kim JH.
    Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Cancer Chemother Pharmacol 66:425-431, 2010
    Moon YW, Rha SY, Jeung HC, Kim C, Hong MH, Chang H, Roh JK, Noh SH, Kim BS, Chung HC.
    Outcomes of multiple salvage chemotherapy in advanced gastric cancer: implications for clinical practice and trial design.
    Cancer Chemother Pharmacol 66:797-805, 2010
    Jung M , Shin HJ , Rha SY , Jeung HC , Hong S , Moon YW , Kim HS , Oh KJ , Yang WI , Roh JK , Chung HC.
    The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up.
    Ann Surg Oncol 17: 3259-3268, 2010
  • 2009

  • *
    Rha SY, Jeung HC, Seo MY, Kim SC, Yang WI, Moon YW, Chung HC.
    Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery.
    Int J Oncol 34:837-846, 2009
    Moon YW, Sohn JH, Kim YT, Chang H, Jeong JH, Lee YJ, Chang J, Kim SK, Jung M, Hong S, Choi SH, Kim JH.
    Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer.
    Anticancer Res 29:4243-4249, 2009
    Moon YW, Rha SY, Zhang X, Jeung HC, Yang WI, Kwon O, Jeong JH, Cheon SH, Yoo NC, Chung HC.
    Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer.
    J Surg Oncol 100:459-465, 2009
  • 2008

  • *
    Jeung HC, Moon YW, Rha SY, Yoo NC, Roh JK, Noh SH, Min JS, Kim BS, Chung HC.
    Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
    Ann Oncol 19:520-526, 2008
  • 2007

  • *
    Moon YW, Choi ST, Cho BC, Choi HJ, Kim YT.
    A case of successful intrapleural chemotherapy with cisplatin plus cytarabine for intractable malignant pleural effusion.
    Yonsei Med J 48:1035-1038, 2007
    Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC.
    Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean institute.
    Ann Surg Oncol 14:2730-2737, 2007
    Moon YW, Jeung HC, Rha SY, Choi YH, Yang WI, Chung HC.
    Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer.
    Breast Cancer Res Treat 104:31-37, 2007
    Sohn JH, Moon YW, Lee CG, Kim GE, Chung KY, Chang J, Kim SK, Kim YS, Choi BW, Choi HJ, Kim JH.
    Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. (*Both equally contributed).
    Cancer 109:1845-1850, 2007
    Moon YW, Sohn JH, Kim YT, Chang H, Jeong JH, Lee YJ, Chang J, Kim SK, Jung M, Hong S, Choi SH, Kim JH.
    Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based two-drug chemotherapy for unresectable non-small cell lung cancer. (*Both equally contributed).
    Cancer 109:1829-1835, 2007
  • 2006

  • *
    Sohn JH, Choi HJ, Chang J, Kim SK, Lee CG, Chung KY, Kim DJ, Cho BC, Shin SJ, Moon YW, Kim JH.
    A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
    Lung Cancer 54:365-370, 2006
  • 2005

  • *
    Moon YW, Hahn JS, Lee ST, Roh JK, Yang WI, Suh CO.
    Clinical characteristics and treatment outcome of primary mediastinal lymphoma.
    Korean J Med 68:417 426, 2005 (Korean)
    Rha SY, Moon YH, Jeung HC, Kim YT, Sohn JH, Yang WI, Suh CO, Kim GE, Roh JK, Chung HC.
    Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.
    Breast Cancer Res Treat 90:215-221, 2005
    Moon YW, Rha SY, Jeung HC, Yang WI, Suh CO, Chung HC.
    Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis.
    Ann Oncol 16:1778-1785, 2005
  • 2004

  • *
    Kim JB, Oh SJ, Lee SC, Kim WH, Moon YW, Jun DW, Yang JY.
    One case of with the right ventricular free wall vegetive infective endocarditis complicated by pulmonary embolism in a patient with ventricular septal defect.
    Korean J Med 66:625-629, 2004 (Korean)
    Moon YW, Kim JH, Kang WC, Park BE, Ko YG, Choi DH, Yu KJ.
    A case of acute mesenteric infarction following coronary artery bypass graft.
    Korean J Med 66:317-320, 2004 (Korean)
    Jung JH1, Min PK, Moon YW, Shim WH.
    Congestive heart failure and a swollen breast.
    Lancet 363:210, 2004
    Jeung HC, Moon YW.
    Chemotherapy in cancer patients with comorbidity.
    J Korean Gastric Cancer Assoc 4:59-74, 2004 (Korean)
  • 2000

  • *
    Moon YW, Yang H, Jung HC, Rha SY, Kim TS, Yoo NC, Noh SH, Roh JK, Min JS, Kim BS, Chung HC.
    Application of gabexate mesylate IC50 against MMP - 9 using ex vivo model in gastric cancer: prognostic factor and selection criteria for anti - MMP treatment.
    J Korean Cancer Assoc 32:7-18, 2000 (Korean)